TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00075582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT02154581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLActive implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLActive implant
Study: NCT06241079

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention

Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention
Study: NCT03194555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Naltrexone and Acetaminophen Combination
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study: NCT00642239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Study: NCT00532584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
Study: NCT02535845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: Project Voice tablet-based intervention plus informational video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Informational Video
Description: Informational video only
Study: NCT02254928

Intervention type: DRUG
Group type: OTHER
Intervention: Corifollitropin alfa
Description: One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.

Intervention type: DRUG
Group type: OTHER
Intervention: Corifollitropin alfa
Description: One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
Study: NCT02045797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Lyophile
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Lyophile
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Lyophile
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsules
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsules
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsules
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Study: NCT01750099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Spinal-epidural
Description: See arm description

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Lumbar epidural
Description: See arm description
Study: NCT01801644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin
Description: gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
Study: NCT04178187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caps Lactolevure
Description: One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caps Placebo
Description: Caps Placebo
Study: NCT00832585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept 15mg IM every week for 12 weeks
Study: NCT02360592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: In arm 2 and 3, interferon alfa-2b is used for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: In arm 2 and 3, interferon alfa-2b is used for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: In arm 3, Interleukin 2 is used for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: In arm 3, Hepatitis B Vaccine is used for 48 weeks
Study: NCT01374087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg
Description: Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy: Low or high dose rate.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy: Low or high dose rate.
Study: NCT03809507

Intervention type: OTHER
Intervention: Qualtrics survey questions
Description: Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication
Study: NCT00206414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa Day 1 given with Arimidex and Faslodex
Description: timing of administration of iressa is the study factor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iressa Day 21 given with Arimidex and Faslodex
Description: Timing of Iressa is the study factor
Study: NCT04297137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
Study: NCT03384550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation coaching
Description: Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-regulation coaching
Description: Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation coaching
Description: Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planning
Description: A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Incentives
Description: Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
Study: NCT03475966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
Study: NCT04701580

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-MR
Description: Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MR
Description: Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
Study: NCT02933840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlertWatch
Description: AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
Study: NCT04143217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 200 to 600 mg/day
Study: NCT05017129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inmates Care
Description: The single intervention is a computer-based learning program.
Study: NCT03225027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trait Emotional Intelligence Questionnaire
Description: To evaluate their emotional intelligence.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trait Emotional Intelligence Questionnaire
Description: To evaluate their emotional intelligence.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive And Negative Syndrome Scale
Description: Evaluating the clinical status of patients with schizophrenia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini International Neuropsychiatric Interview
Description: Evaluating the exclusion criteria in healthy participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini International Neuropsychiatric Interview
Description: Evaluating the exclusion criteria in healthy participants.
Study: NCT03698786

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
Study: NCT02428621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twicare® appliance
Description: Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Herbst appliance
Description: Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).
Study: NCT03209648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450
Description: Debio 1450, 40 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole, 20 mL of 10 mg/mL solution.
Study: NCT03475966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Description: Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation techniques
Description: Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
Study: NCT03394482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 5 mg clinical formulation
Description: Lu AF35700 tablets 5 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 5 mg commercial formulation
Description: Lu AF35700 tablets 5 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 10 mg clinical formulation
Description: Lu AF35700 tablets 10 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 10 mg commercial formulation
Description: Lu AF35700 tablets 10 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 20 mg clinical formulation
Description: Lu AF35700 tablets 20 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 20 mg commercial formulation
Description: Lu AF35700 tablets 20 mg oral single dose
Study: NCT00735787

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
Study: NCT03006744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological awareness training
Description: Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reading enjoyment training
Description: Training on how to make reading enjoyable for children.
Study: NCT03251508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut OIT
Description: Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
Study: NCT01786954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonopen applanation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonopen applanation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation
Study: NCT04234035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid to facilitated shared decision-making

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Educational Material (informational pamphlet)
Description: Pamphlet with information about kidney stones

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Educational Material (informational pamphlet)
Description: Pamphlet with information about kidney stones